Abstract
Hepatitis B virus (HBV) is a major cause of chronic liver disease worldwide. HBV reactivation with immunosuppressive treatments is thoroughly described, and is most widely reported in patients who have chronic HBV infection, when hepatitis B surface antigen (HBsAg) is positive, in connection with chemotherapy used to treat lymphoma. However, reactivation can also occur in patients who have prior resolved HBV infection, in whom HBsAg is negative but antibody to hepatitis B core antigen is positive. The antiviral drug lamivudine is highly efficacious in preventing HBV reactivation in these circumstances.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
